Boston, Massachusetts 2021-09-13 04:50:51 –
OOne-third of the use of anti-cancer drugs given rapid approval remained on product labeling, even after follow-up did not confirm its benefits. New analysis At the BMJ. At the same time, widely read guidelines for physicians continued to recommend these treatments.
The problem is Fast approval program It was created almost 30 years ago to speed up the availability of medicines for serious conditions where medical needs are not met. However, because the program allows regulators to rely on surrogate measures that may prove effective in exchange for access, pharmaceutical companies are conducting trials to benefit patients as the drug intended. You need to confirm that later.
Cancer drug indications remain on labels after trials fail to confirm benefits Source link Cancer drug indications remain on labels after trials fail to confirm benefits